阿法替尼|T2303

价格	￥178
包装	100mg

最小起订量	1mg
发货地	上海
更新日期	2024-09-14

QQ交谈微信洽谈

产品详情

中文名称:阿法替尼	英文名称:(S)-Afatinib
CAS:439081-18-2	品牌: TargetMol
产地: 美国	保存条件: Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
纯度规格: 99.96%	产品类别: 抑制剂
货号: T2303

Product Introduction

Bioactivity

名称	(S)-Afatinib
描述	(S)-Afatinib (BIBW2992) is an irreversible EGFR family inhibitor with IC50s of 0.5/0.4/10/14/1 nM for EGFRwt, EGFR (L858R), EGFR (L858R/T790M), HER2, and HER4, respectively.
细胞实验	Cells (1×10^4) were transferred into each well of a 96-well plate and cultured over night in serum-free media for EGFR phosphorylation assay. After addition of test compounds on the next day, the plates were then incubated at 37°C for 1 hour. EGF-stimulation was done at 100 ng/ml for 10 min at room temperature. Cells were washed with ice cold PBS before extraction with 120 μl per well HEPEX buffer and shaken for 1 h at room temperature. In all 2×10^4 cells per well was used for HER2 phosphorylation assay. Streptavidin precoated plates were coated with anti-EGFR-biotin at 1:100 dilution with blocking buffer and c-erb2/HER2 oncoprotein Ab-5(Clone N24)-Biotin. Extracts from above steps were then transferred to the antibody-coated wells and incubated for 1 h at room temperature. Assessment of color development is described in Supplementary information. Extinction was measured at 450 nm. The data generated were analysed by the program PRISM. Normalized values were used to calculate the IC50 by a nonlinear regression curve fit (variable slope) [1].
激酶实验	The wild type tyrosine kinase domain of the human EGFR, as well as the EGFR L858R/T790M double mutant, were fused to Glutathione-S-transferase (GST) and extracted as described in Supplementary methods. The L858R mutant was purchased from Upstate. Enzyme activity was then assayed in the presence or absence of serial inhibitor dilutions performed in 50% Me2SO. A random polymer pEY (4:1) from Sigma was used as substrate. Biotinylated pEY was added as a tracer substrate. The kinase domain of HER2 was cloned using baculovirus system and extracted similarly to that of EGFR kinase domain. Detailed procedures for EGFR, HER2, SRC, BIRK and VEGFR2 kinase activity assays are included in Supplementary information [1].
动物实验	Six weeks old female athymic nude mice (nu/nu) weighing about 16-20 gram were housed by Laboratory Animal Services Centre of The Chinese University of Hong Kong. The experiment was conducted by researchers under license from the Hong Kong Government Department of Health and according to approval given by Animal Experimentation Ethics Committee of the Chinese University of Hong Kong. ESCC xenografts were established by inoculating HKESC-2 (0.6 × 10^5 cells re-suspended in 50 μl of HBSS-buffer) subcutaneously into both flanks of the nude mice. When tumor size reached to 4-6 mm diameter, they were randomized in either treatment (15 mg/kg) or vehicle control group. Afatinib for treatment was prepared by dissolving in 0.5% methylcellulose before administration. Either drug or vehicle was administered to mouse by oral gavage in a schedule of 5 days on plus 2 days off for two weeks. Drug efficacy was evaluated by monitoring the change in tumor size with caliper. Tumor volume was calculated with the formula Tumor Volume = (width2 × length)/2 [2].
体外活性	(S)-Afatinib对EGFR与HER2的野生型及其突变形式展示出强大活性（IC50分别为：EGFRwt 0.5 nM、EGFR L858R 0.4 nM、EGFR L858R/T790M 10 nM、HER2 14 nM）。在人类乳腺癌细胞系中，使用100 nM (S)-Afatinib足以阻止hereregulin刺激的HER3磷酸化作用[1]。食管鳞状细胞癌（ESCC）细胞系对于afatinib敏感，IC50浓度处于较低μM范围内（72小时培养下：HKESC-1 = 0.002 μM、HKESC-2 = 0.002 μM、KYSE510 = 1.090 μM、SLMT-1 = 1.161 μM与EC-1 = 0.109 μM）。ErbB家族下游效应物如pAKT、pS6与pMAPK的磷酸化在HKESC-2与EC-1中被显著抑制。两个细胞系在暴露于afatinib后24小时观察到凋亡现象[2]。
体内活性	每日口服BIBW2992，剂量为20 mg/kg，连续25天治疗，显著促进肿瘤退化并下调EGFR和AKT的磷酸化水平。通过NCIH1975细胞系（表达EGFR L858R/T790M）引起的异种移植瘤形成，经BIBW2992处理后被有效控制，20 mg/kg剂量的T/C值为12% [1]。Afatinib能有效抑制小鼠体内HKESC-2肿瘤生长，且无明显毒副作用；单独使用Afatinib在体内模型中对食管鳞状细胞癌（ESCC）表现出优秀的生长抑制效果 [2]。
存储条件	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
溶解度	H2O : < 1 mg/mL (insoluble or slightly soluble) DMSO : 90 mg/mL (185.2 mM) Ethanol : 12 mg/mL (24.7 mM) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 9 mg/mL (18.52 mM), Suspension. Working solution is recommended to be prepared and used immediately.
关键字	BIBW 2992 \| Afatinib \| BIBW-2992
相关产品	Lapatinib \| Neratinib \| Chalcone \| Gefitinib \| Erlotinib \| Osimertinib \| Erlotinib hydrochloride \| Lidocaine Hydrochloride hydrate \| Genistein
相关库	经典已知活性库 \| 已知活性化合物库 \| 自噬库 \| 抗结直肠癌化合物库 \| 激酶抑制剂库 \| FDA 上市药物库 \| FDA 上市激酶抑制剂库 \| 酪氨酸激酶分子库 \| 儿童药物库 \| 人代谢物化合物库

关键字： BIBW2992|||阿法替尼|||(S)-阿法替尼|TargetMol

公司简介

上海陶术生物科技有限公司为美国Target Molecule Corp. ( Target Mol ) 在上海建立的全资子公司。我们与美国波士顿、德国慕尼黑的同事一起，为北美、欧洲和亚洲从事药物研发和生物学研究的科学家提供优质的产品和专业的服务。公司下设筛选事业部，化学事业部，生物事业部和新材料部。从虚拟筛选到实体化合物分子供应；从商业化产品销售到个性化定制合成；从对明确靶点的分子筛选到对明确分子的多靶点筛选，从高通量筛选到化学结构优化，我们都可以满足您的科研用品及技术服务的需求。经过在中国市场五年的精心耕耘，我们已成为筛选化合物领域优秀的供应商，为超过五百家学校和各类企业提供了品质卓越的小分子化合物和药物筛

成立日期	2013-04-18 （12年）	注册资本	566.2651万人民币
员工人数	100-500人	年营业额	￥ 1亿以上
主营行业	化学试剂,生物活性小分子	经营模式	贸易,试剂,定制,服务

TargetMol中国（陶术生物）

VIP 12年

公司成立：12年
注册资本：566.2651万人民币
企业类型：有限责任公司(自然人投资或控股)
主营产品：小分子抑制剂，药物筛选化合物库，天然产物，活性分子化合物等
公司地址：上海市闸北区江场三路28号4楼

进入店铺

询盘

店内推荐

3-吲哚甲醛|T8105

￥298

化合物 GS-441524|T7222

￥176

钩吻碱|T5S0662

￥328

阿法替尼|T2303相关厂家报价

产品名称	价格		公司名称	报价日期
阿法替尼	￥100	VIP12年	湖北威德利化学科技有限公司	2024-10-16
阿法替尼	￥300.00	VIP7年	上海博景化工有限公司	2024-10-16
阿法替尼439081-18-2	询价	VIP3年	河南威梯希化工科技有限公司	2024-10-16
阿法替尼	询价	VIP5年	武汉鼎信通药业有限公司	2024-10-16
阿法替尼	询价	VIP5年	武汉鼎信通药业有限公司	2024-10-16
Afatinib	询价	VIP9年	沧州恩科医药科技有限公司	2024-10-16
阿法替尼-439081-18-2	￥548	VIP3年	湖北魏氏化学试剂股份有限公司	2024-10-16
阿法替尼/439081-18-2	询价	VIP3年	湖北魏氏化学试剂股份有限公司	2024-10-16
阿法替尼	询价	VIP11年	寿光佳胜化工有限公司	2024-10-15
阿法替尼	询价	VIP9年	湖北威德利化学科技有限公司	2024-10-15

内容声明:
以上所展示的信息由商家自行提供，内容的真实性、准确性和合法性由发布商家负责。商家发布价格指该商品的参考价格，并非原价，该价格可能随着市场变化，或是由于您购买数量不同或所选规格不同而发生变化。最终成交价格，请咨询商家，以实际成交价格为准。请意识到互联网交易中的风险是客观存在的